文献速递免疫规划

AddaS03与Poly I:C佐剂联合增强RBD疫苗抗体与Th1偏向T细胞应答

Synergistic effect of AddaS03 and poly I:C adjuvants on antibody titers and Th1-biased T cell responses following RBD vaccination in BALB/c mice.
PubMed 文献 · Vaccine · 2026-08-22

在BALB/c小鼠中评估RBD二聚体疫苗联合AddaS03与Poly I:C佐剂的体液和细胞免疫原性。联合佐剂保留AddaS03的强体液应答并赋予Poly I:C的Th1偏向特性,产生优于单佐剂的协同效应,改善抗体亲和力、增加抗体分泌细胞并增强多功能CD4+ T细胞诱导,同时鉴定三个RBD II类T细胞表位。

要点

  • AddaS03与Poly I:C联合具有协同佐剂效应,优于任一单佐剂。
  • 联合佐剂增强抗体亲和力及脾和骨髓抗体分泌细胞生成。
  • 联合佐剂促进多功能细胞因子产生CD4+ T细胞及Th1偏向。

核心结论

  • AddaS03与Poly I:C联合是调控和增强RBD疫苗免疫应答的有效策略。

研究设计与样本

  • 使用 ancestral Wuhan株来源的RBD二聚体,在BALB/c小鼠中评估联合AddaS03与Poly I:C佐剂的体液和细胞免疫原性。

主要发现

  • 联合佐剂保留AddaS03典型强体液应答,并赋予Poly I:C的Th1偏向特性。
  • 联合佐剂产生协同效应,超过各单佐剂效果。
  • 联合佐剂改善抗体亲和力,增加脾和骨髓抗体分泌细胞生成。
  • 联合佐剂增强多功能细胞因子产生CD4+ T细胞诱导。
  • 鉴定RBD内三个II类T细胞表位:肽6(351-YAWNRKRISNCVADYSV-367)、肽19(442-SKVGGNYNYLYRLFRK-458)、肽20(449-YNYLYLYRLFRKSNLKPFE-465)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The COVID-19 pandemic caused over seven million deaths, and disease control relied largely on mass immunization campaigns. Although diverse vaccine platforms were used, most formulations targeted the Spike protein because of its central role in virus entry. Persistent viral evolution and global vaccine inequity highlight the need for alternative strategies, particularly for low- and middle-income countries. In this scenario, recombinant protein-based vaccines are attractive due to low cost, established manufacturing pipelines and well-characterized safety profiles. The receptor binding domain (RBD) of Spike is an appealing antigen due to its relatively simple structure, proven immunogenicity - especially in multimerized formats - and because it harbors most neutralizing antibody epitopes. Protein-based vaccines, however, rely on the use of adjuvants to optimize antigen-specific immunity. METHODS: We used an RBD dimer derived from the ancestral Wuhan strain as a well-characterized protein to evaluate the humoral and cellular immunogenicity of combined AddaS03 and Poly I:C adjuvants in BALB/c mice. RESULTS: The adjuvant combination preserved the strong humoral responses typically induced by AddaS03 while conferring the Th1-skewing properties of Poly I:C, producing a synergistic effect that exceed those of each adjuvant alone. Specifically, the combination improved antibody affinity, increased the generation of antibody- secreting cells in spleen and bone marrow, and enhanced the induction of polyfunctional, cytokine-producing CD4+ T cells. Additionally, we mapped and characterized three class II T cell epitopes within RBD: peptide 6 (351-YAWNRKRISNCVADYSV-367), peptide 19 (442-SKVGGNYNYLYRLFRK-458) and peptide 20 (449-YNYLYRLFRKSNLKPFE-465). CONCLUSIONS: Combining AddaS03 and Poly I:C adjuvants is a potent strategy to modulate and enhance immune responses elicited by an RBD-based vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Nunes JPDS, Daher IP, Pires ADS, et al. Synergistic effect of AddaS03 and poly I:C adjuvants on antibody titers and Th1-biased T cell responses following RBD vaccination in BALB/c mice. Vaccine. 2026. PMID: 42632374. doi:10.1016/j.vaccine.2026.129073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。